Alprazolam
- Generic Name
- Alprazolam
- Brand Names
- Niravam, Xanax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H13ClN4
- CAS Number
- 28981-97-7
- Unique Ingredient Identifier
- YU55MQ3IZY
- Background
Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981.
- Indication
Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults. Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.
Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.
- Associated Conditions
- Generalized Anxiety Disorder, Panic Disorder
Opioid/Benzodiazepine Polydrug Abuse: Aim 3
- Conditions
- Polysubstance AbuseOpioid AbuseBenzodiazepine Abuse
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Wayne State University
- Target Recruit Count
- 24
- Registration Number
- NCT05006079
- Locations
- 🇺🇸
Tolan Park Medical Building, Detroit, Michigan, United States
Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim
- Conditions
- Driving BehaviorDriving Under the Influence
- Interventions
- Drug: Placebo (Lactose) Capsule
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Timothy L. Brown
- Target Recruit Count
- 13
- Registration Number
- NCT04970342
- Locations
- 🇺🇸
National Advanced Driving Simulator, Iowa City, Iowa, United States
A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 14
- Registration Number
- NCT04857307
- Locations
- 🇺🇸
Up0100 105, Memphis, Tennessee, United States
🇺🇸Up0100 103, Honolulu, Hawaii, United States
🇺🇸Up0100 106, Cincinnati, Ohio, United States
A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma
- Conditions
- Participants With Mild AsthmaHealthy Study Participants
- Interventions
- Other: Placebo
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 78
- Registration Number
- NCT04802746
- Locations
- 🇺🇸
Up0099 102, Raleigh, North Carolina, United States
🇺🇸Up0099 101, North Dartmouth, Massachusetts, United States
Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 30
- Registration Number
- NCT04782388
- Locations
- 🇺🇸
Up0101 101, Anaheim, California, United States
Role of Alprazolam in the Management of Acute Coronary Syndrome
- Conditions
- Myocardial InfarctionHeart DiseasesAcute Coronary SyndromeST Elevation Myocardial InfarctionAnxiety
- Interventions
- Other: Placebo
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Sohaib Ashraf
- Target Recruit Count
- 48
- Registration Number
- NCT04715269
- Locations
- 🇵🇰
Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan
A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects
- Conditions
- Panic Disorder
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 56
- Registration Number
- NCT04592536
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Zernikedreef 8, Netherlands
Preoperative Use of Alprazolam and Hydroxyzine in Anxiety
- Conditions
- Agitation on Recovery From Sedation
- Interventions
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Istanbul Medeniyet University
- Target Recruit Count
- 90
- Registration Number
- NCT04184141
Licorice Botanical Dietary Supplements - Metabolism and Safety in Women
- Conditions
- Food-drug Interaction
- Interventions
- Dietary Supplement: Licorice
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 19
- Registration Number
- NCT03948243
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Assessment of Effect of Rapastinel on Driving Performance
- Conditions
- Driving Performance
- Interventions
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Target Recruit Count
- 107
- Registration Number
- NCT03814733
- Locations
- 🇺🇸
Collaborative Neuroscience Network, San Clemente, California, United States
🇨🇦Algorithme Pharma, Aurora, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.